GB1275 is a first-in-class CD11b modulator that interferes with the balance between immune-suppressive and proactive immune reactions, specifically reducing MDSCs and TAMs at the tumor site, converting M2 immunosuppressive TAMs into an M1 phenotype, and increasing the levels of activated CD8+ T-cells in preclinical tumor models [57]. The gene discussed is CD8A; the disease is neoplasm.